GYRE Gyre Therapeutics PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: GYRE
- PE Ratio
The current price-to-earnings ratio for Gyre Therapeutics stock as of Jul 11, 2025 is 93.63. This is calculated based on the current EPS of $0.08 and the stock price of $7.49 per share.
GYRE PE ratio history
The average historical PE ratio of Gyre Therapeutics for the last nine years is 64.88. The current PE ratio of 93.63 is 44% above the historical average. In the past nine years, GYRE's PE ratio was at its highest in the Dec 2022 quarter at 197.8, when the stock price was $7.91 and the EPS was $0.04. The lowest value was in the Mar 2023 quarter, when it reached 0.44 with a price of $3.11 and an EPS of $6.98.
Gyre Therapeutics PE ratio by year
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 86.43 | N/A | $12.1 | $0.14 |
| 2023 | N/A | N/A | $25.69 | -$1.41 |
| 2022 | 197.8 | N/A | $7.91 | $0.04 |
| 2021 | N/A | N/A | $13.71 | -$43.05 |
| 2020 | N/A | N/A | $94.65 | -$43.95 |
| 2019 | N/A | N/A | $102.15 | -$69 |
| 2018 | N/A | N/A | $118.35 | -$40.2 |
| 2017 | N/A | N/A | $204.6 | -$111.75 |
| 2016 | N/A | N/A | $146.25 | -$326.25 |
| 2015 | N/A | N/A | $704.25 | -$749.85 |
| 2014 | N/A | N/A | $4,142.25 | -$4,047.75 |
| 2013 | N/A | N/A | $6,536.25 | -$6,140.25 |
| 2012 | N/A | N/A | $6,898.5 | -$330.75 |
| 2011 | N/A | N/A | $8,772.75 | -$425.25 |
| 2010 | 69.74 | N/A | $41,737.5 | $598.5 |
Gyre Therapeutics PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2025 | 96.5 | 11.65% | $7.72 | $0.08 |
| Dec 2024 | 86.43 | N/A | $12.1 | $0.14 |
| Sep 2024 | N/A | N/A | $12.54 | -$1.4 |
| Jun 2024 | N/A | N/A | $11.93 | -$1.35 |
| Mar 2024 | N/A | N/A | $17.48 | -$1.36 |
| Dec 2023 | N/A | N/A | $25.69 | -$1.41 |
| Sep 2023 | N/A | N/A | $7.23 | -$15.13 |
| Jun 2023 | N/A | N/A | $5.27 | -$17.59 |
| Mar 2023 | 0.44 | -99.78% | $3.11 | $6.98 |
| Dec 2022 | 197.8 | 14,772.18% | $7.91 | $0.04 |
| Sep 2022 | 1.33 | N/A | $7.56 | $5.7 |
| Jun 2022 | N/A | N/A | $26.7 | -$3.9 |
| Mar 2022 | N/A | N/A | $9.9 | -$38.1 |
| Dec 2021 | N/A | N/A | $13.71 | -$43.05 |
| Sep 2021 | N/A | N/A | $61.65 | -$46.65 |
GYRE Price vs fair value
GYRE average PE ratio chart
The current PE ratio of GYRE is above the 3, 5 and 10-year historical averages.
GYRE PE vs peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| GYRE Gyre Therapeutics Inc | 93.63 | $702.24M |
| OLMA Olema Pharmaceuticals Inc | N/A | $318.16M |
| OMER Omeros Corp | N/A | $213.86M |
| VIVS VivoSim Labs Inc. | N/A | $5.04M |
| ORIC Oric Pharmaceuticals Inc | N/A | $789.08M |
| ORMP Oramed Pharmaceuticals Inc | N/A | $87.22M |
Frequently asked questions
What is Gyre Therapeutics's PE ratio?
The price to earnings ratio for GYRE stock is 93.63 as of Jul 11, 2025.
What is the 3-year average PE ratio for Gyre Therapeutics (GYRE)?
Over the last 3 years, the average price to earnings ratio for GYRE stock is 76.5.
What is the 5-year average PE ratio for Gyre Therapeutics (GYRE)?
Over the last 5 years, the average price to earnings ratio for GYRE stock is 76.5.
What is the highest PE ratio for GYRE?
Over the last nine years, the quarterly PE ratio reached a historic high of 197.8 in the Dec 2022 quarter.
How does the current PE ratio for GYRE compare to its historical average?
The current price to earnings ratio of GYRE is 44% higher than the 9-year historical average.
Why is Gyre Therapeutics's PE ratio so high?
A company with a higher PE ratio may indicate that the market has higher growth expectations for the company's future earnings or profitability.
How is GYRE's PE ratio calculated (Gyre Therapeutics PE ratio formula)?
The PE ratio is calculated by dividing the most recent price of a stock by its trailing twelve months EPS. As of today (Jul 11, 2025), Gyre Therapeutics's stock price is $7.49. The earnings per share for the trailing twelve months (TTM) ending Mar 2025 is $0.08. Therefore, Gyre Therapeutics's P/E ratio for today is 93.63. PE RATIO(93.63) = STOCK PRICE($7.49) / TTM EPS($0.08)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.